{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:36:38Z","timestamp":1776926198585,"version":"3.51.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Kaposiform lymphangiomatosis (KLA) is an ultrarare disease characterized by abnormal lymphatic vessel proliferation due to hyperactivation of the Rat sarcoma virus (RAS) signaling pathway, resulting in multifocal lymphatic malformations (LMs) that can potentially involve multiple organ systems. Its distinctive histologic features include the presence of clusters of spindle cells expressing clusters of differentiation 31 (CD31), cluster of differentiation 34 (CD34), podoplanin (D2-40), prospero homeobox protein 1 (PROX1), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), along with abnormal lymphatic vessels. Sirolimus is recommended as a treatment option, particularly for patients without known mutations. This study aimed to examine the long-term therapeutic effects of sirolimus treatment in adult patients with KLA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Between 2016 and 2024, KLA was diagnosed in three women, aged 21, 35, and 46\u202fyears, based on clinical presentation, laboratory findings, and imaging studies, and the diagnosis was confirmed by histological examination. The administration of sirolimus was initiated in all three cases at a therapeutic dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment resulted in clinical improvement, partial regression, and subsequent stabilization of fluid volume in the pleural cavities, along with reductions in the severity of anemia and hypofibrinogenemia, accompanied by a decrease in D-dimer concentration. Sirolimus proved to be a relatively effective treatment in this group of KLA patients; however, some beneficial effects were not sustained after 5\u202fyears of follow-up. The most common side effects included mucositis and lipid disorders. We also reviewed the literature regarding sirolimus treatment in KLA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, sirolimus in KLA patients is an effective treatment option with acceptable toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1705297","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:37:27Z","timestamp":1776922647000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Kaposiform lymphangiomatosis\u2014the effects of long-term treatment with sirolimus: case series study and review of the literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Magdalena","family":"Bilny-Paluch","sequence":"first","affiliation":[{"name":"The Third Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Institute","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Piekarczyk","sequence":"additional","affiliation":[{"name":"The Third Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Institute","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"B\u0142asi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Tuberculosis and Lung Diseases Institute","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Szo\u0142kowska","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Tuberculosis and Lung Diseases Institute","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Polaczek","sequence":"additional","affiliation":[{"name":"The Third Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Institute","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Radzikowska","sequence":"additional","affiliation":[{"name":"The Third Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Institute","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"ref1","year":"2025"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e30219","DOI":"10.1002\/pbc.30219","article-title":"Kaposiform lymphangiomatosis: diagnosis, pathogenesis, and treatment","volume":"70","author":"McDanielC","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1097\/PAS.0000000000001898","article-title":"Kaposiform lymphangiomatosis: pathologic aspects in 43 patients","volume":"46","author":"Perez-Atayde","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.humpath.2022.02.010","article-title":"Cellular variant of kaposiform lymphangiomatosis: a report of three cases, expanding the morphologic and molecular genetic spectrum of this rare entity","volume":"122","author":"Allen-Rhoades","year":"2022","journal-title":"Hum Pathol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jpeds.2013.10.013","article-title":"Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly","volume":"164","author":"Croteau","year":"2014","journal-title":"J Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/pbc.25914","article-title":"Clinical features and prognosis of generalized lymphatic anomaly, Kaposiform Lymphangiomatosis, and Gorham-stout disease","volume":"63","author":"Ozeki","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/pbc.25278","article-title":"Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder","volume":"62","author":"Fernandes","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e27790","DOI":"10.1002\/pbc.27790","article-title":"Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis","volume":"66","author":"Boscolo","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e064","DOI":"10.1097\/JOVA.0000000000000064","article-title":"The VASCERN-VASCA working group diagnostic and management pathways for venous malformations","volume":"4","author":"Dompmartin","year":"2023","journal-title":"J Vascular Anomalies"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.radcr.2023.10.078","article-title":"Challenging diagnosis of Kaposiform lymphangiomatosis: unveiling a rare primary lymphatic disorder","volume":"19","author":"Ospino","year":"2024","journal-title":"Radiol Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e30419","DOI":"10.1002\/pbc.30419","article-title":"Pathogenic variants in PIK3CA are associated with clinical phenotypes of kaposiform lymphangiomatosis, generalized lymphatic anomaly, and central conducting lymphatic anomaly","volume":"70","author":"Grenier","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e27878","DOI":"10.1002\/pbc.27878","article-title":"Potential biomarkers of kaposiform lymphangiomatosis","volume":"66","author":"Ozeki","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.20452\/pamw.14949","article-title":"A young woman with enlarged hilar and mediastinal lymph nodes","volume":"129","author":"Radzikowska","year":"2019","journal-title":"Pol Arch Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1164\/rccm.201612-2421IM","article-title":"Kaposiform lymphangiomatosis with human papillomavirus infection","volume":"195","author":"Radzikowska","year":"2017","journal-title":"J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"23247096231166678","DOI":"10.1177\/23247096231166678","article-title":"Do Bom-Sucesso M. Kaposiform lymphangiomatosis in a male adolescent: a clinical challenge and the role of genetics","volume":"11","author":"Pereira-Nunes","year":"2023","journal-title":"JIM- HICR"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1513\/AnnalsATS.201308-287BC","article-title":"Kaposiform lymphangiomatosis, a newly characterized vascular anomaly presenting with hemoptysis in an adult woman","volume":"11","author":"Safi","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1183\/16000617.0018-2016","article-title":"Thoracic involvement in generalized lymphatic anomaly (or lymphangiomatosis)","volume":"25","author":"Luisi","year":"2016","journal-title":"Eur Respir Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-018-0934-z","article-title":"Sirolimus is efficacious in treatment for extensive and\/or complex slow-flow vascular malformations: a monocentric prospective phase II study","volume":"13","author":"Hammer","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13023-021-01893-3","article-title":"Sirolimus in the treatment of kaposiform lymphangiomatosis","volume":"16","author":"Zhou","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-019-1118-1","article-title":"The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies","volume":"14","author":"Ozeki","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1446046","DOI":"10.3389\/fmed.2024.1446046","article-title":"Targeted therapies for vascular malformations","volume":"1","author":"Kane","year":"2024","journal-title":"Front Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/pbc.25422","article-title":"Successful treatment of kaposiform lymphangiomatosis with sirolimus","volume":"62","author":"Wang","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00432-013-1549-3","article-title":"Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma","volume":"140","author":"Kai","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.4161\/cc.6.24.5085","article-title":"All roads lead to mTOR: integrating inflammation and tumor angiogenesis","volume":"6","author":"Lee","year":"2007","journal-title":"Cell Cycle"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00431-015-2572-y","article-title":"Sirolimus for the treatment of children with various complicated vascular anomalies","volume":"174","author":"Lackner","year":"2015","journal-title":"Eur J Pediatr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0036-1593383","article-title":"Sirolimus in the treatment of vascular anomalies","volume":"27","author":"Triana","year":"2017","journal-title":"Eur J Pediatr Surg"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jvs.2021.04.071","article-title":"A prospective multicenter study of sirolimus for complicated vascular anomalies","volume":"74","author":"Ji","year":"2021","journal-title":"J Vasc Surg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1600016","DOI":"10.1183\/13993003.50016-2016","article-title":"ERS\/ATS standards for single-breath carbon monoxide uptake in the lung","volume":"49","author":"Graham","year":"2017","journal-title":"Eur Respir J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.jpedsurg.2019.12.021","article-title":"Effectiveness of sirolimus in the treatment of complex lymphatic malformations: single center report of 56 cases","volume":"55","author":"Tian","year":"2020","journal-title":"J Pediatr Surg"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12890-025-03723-9","article-title":"Lymphatic malformations involving the thorax in children: a retrospective cohort study","volume":"25","author":"Han","year":"2025","journal-title":"BMC Pulm Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1335469","DOI":"10.3389\/fmed.2024.1335469","article-title":"Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial","volume":"11","author":"Ozeki","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud","year":"2023","journal-title":"Genet Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e12324","DOI":"10.15252\/emmm.202012324","article-title":"Kaposiform lymphangiomatosis effectively treated with MEK inhibition","volume":"12","author":"Foster","year":"2020","journal-title":"EMBO Mol Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1038\/s41390-023-02755-3","article-title":"Insights image for \u201ctreatment of severe Kaposiform Lymphangiomatosis positive for NRAS mutation by MEK-inhibition\u201d","volume":"94","author":"Chowers","year":"2023","journal-title":"Pediatr Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1755-9294.2012.01130.x","article-title":"Diffuse pulmonary lymphangiomatosis: Pulmonary lymphatic disorder in an adult","volume":"5","author":"Yoo","year":"2012","journal-title":"Basic and Applied Pathology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s00247-016-3611-1","article-title":"Imaging features of kaposiform lymphangiomatosis","volume":"46","author":"Goyal","year":"2016","journal-title":"Pediatr Radiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1705297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:37:28Z","timestamp":1776922648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1705297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":39,"alternative-id":["10.3389\/fmed.2026.1705297"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1705297","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1705297"}}